Skip to content

Follow-up of Children After Stuttering Treatment

Relapse Following the Lidcombe Program for Preschool Children Who Stutter

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00709072
Enrollment
180
Registered
2008-07-03
Start date
2009-02-28
Completion date
2011-12-31
Last updated
2010-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stuttering

Keywords

stuttering, relapse, Lidcombe Program, Preschool children

Brief summary

This study aims to determine the percentage and predictors of stuttering relapse following treatment with the Lidcombe Program. It will also investigate the effectiveness of sending reminder messages to parents to assist in reducing relapse.

Detailed description

Stuttering treatment becomes more time-consuming and less effective as children become older. Therefore it is crucial to prevent relapse following treatment in the early years. This study will investigate predictors of relapse and assess the effectiveness of a simple two-weekly user-friendly reminder to parents, about when and how to address any re-occurring stuttering after treatment. Results from the study may help to prevent stuttering relapse in this age group in the future.

Interventions

BEHAVIORALSMS (Short Message Service) reminders

SMS reminders sent every 2 weeks

Sponsors

University of Sydney
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* Completion of stage I of Lidcombe Program * Less than 1 percent syllables stuttered at recruitment * Means of receiving SMS email or phone reminder

Design outcomes

Primary

MeasureTime frame
percentage of syllables stutteredsix monthly for three years

Secondary

MeasureTime frame
parent reported stuttering severitysix monthly for three years

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026